Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cefadroxil
- Development stage
- Approved
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cefadroxil is a first-generation cephalosporin antibiotic used to treat bacterial infections such as urinary tract infections, skin and skin structure infections, pharyngitis, and tonsillitis. It works by inhibiting bacterial cell wall synthesis, leading to cell lysis. Cefadroxil is not effective against viral infections like the common cold or flu.
- Brand names
- DuricefUltracef
- Other names
- CefadroxilaCefadroxil monohydrate
02
Targets
PBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on cefadroxil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cefadroxil.